Oyster Point begins enrolment for Phase 3 ONSET-2 study of nasal spray
Category: #health  By Mateen Dalal  Date: 2019-07-26
  • share
  • Twitter
  • Facebook
  • LinkedIn

Oyster Point begins enrolment for Phase 3 ONSET-2 study of nasal spray

The trial is designed to assess the efficacy and safety of OC-01 for treating dry eye disease

Reports confirm that Oyster Point Pharma, a clinical-stage biopharmaceutical company, has recently announced that the first subject has been enrolled in the Phase 3 ONSET-2 clinical study of OC-01 Nasal Spray to treat the symptoms and signs of dry eye disease.

According to CEO and President of Oyster Point Pharma, Jeffrey Nau, Ph.D., M.M.S., after successfully completing the registrational Phase 2b clinical study i.e. ONSET-1, the company has announced the commencement of the second registrational trial, ONSET-2.

It is believed that OC-01 has the potential to change the method used by eye care physicians to treat patients with dry eye disease, owing to the fast onset of action in surging natural tear film production, the capability to substantially improve both symptoms and signs of dry eye disease, and a promising tolerability profile.

The innovative delivery of OC-01 as a nasal spray spares the ocular surface and allows the product’s novel mechanism of action, offering unique benefits to patients and eye care practitioners.

Reportedly, the ONSET-2 clinical trial is a double-masked, randomized, multicentre, placebo-controlled clinical study to assess the efficacy and safety of OC-01 nasal spray for treating the symptoms and signs of dry eye disease.

The study, which will recruit around 750 subjects at around 20 U.S. centers, will investigate two dosages of OC-01 nasal spray, 1.2 mg/ml, and 0.6mg/ml, as compared to placebo nasal spray. The pre-specified primary endpoint of the clinical trial will be the evaluation of tear production as calculated by the percentage of subjects showing a 10 mm or bigger change at week 4 from baseline Schirmer’s Score.

A member of medical advisory board of Oyster Point Pharma and an ophthalmologist at Virginia Eye Consultants, Elizabeth Yeu, M.D., stated that it is inspiring to view the progress Oyster Point is achieving in the development of OC-01. There is a substantial requirement for therapeutic options that can successfully benefit a wide population of patients with dry eye disease.

 

Source Credits: https://oysterpointrx.com/oyster-point-pharma-announces-enrollment-of-first-subject-in-phase-3-clinical-trial-of-nasal-spray-for-dry-eye-disease/

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Hyundai plans to raise stake in China’s Sichuan Hyundai Motor
Hyundai plans to raise stake in China’s Sichuan Hyundai Motor
By Mateen Dalal

Hyundai Motor Company identifies the significance and impact of automobiles, and strives to fulfill its goals by creating new and advanced vehicles that addresses all the vital issues faced by drivers. The automobile giant has effectively become...

TransPerfect expands its portfolio by acquiring Sublime Subtitling
TransPerfect expands its portfolio by acquiring Sublime Subtitling
By Mateen Dalal

With decades of hard work and hands-on experience, TransPerfect has managed to become one of the largest global providers of technology and language solutions for companies worldwide. With over 5,000 global organizations employing its GlobalLink®...

Altran to launch a Digital Therapeutics Innovation Center in Boston
Altran to launch a Digital Therapeutics Innovation Center in Boston
By Mateen Dalal

Digital therapeutics are evidence-based interventions conducted by advanced software programs to manage, treat or prevent clinical disorders. Its adoption has augmented the whole medical industry, making it simpler for practitioner to ...